Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunostem
- Development stage
- Phase 2
- Lead developer
- Altheia Science
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Immunostem is an autologous hematopoietic stem and progenitor cell (HSPC) therapy genetically modified to express human programmed death-ligand 1 (PD-L1), currently under development by Altheia Science for the treatment of recent-onset type 1 diabetes mellitus (T1D). The therapy involves the ex vivo transduction of a patient's own CD34+ HSPCs with a lentiviral vector encoding PD-L1. Once re-infused into the patient, these engineered cells and their progeny are intended to migrate to the pancreas and lymphoid organs to restore immune tolerance by activating the PD-1 pathway on autoreactive T cells. This approach aims to halt the autoimmune destruction of insulin-producing beta cells and preserve residual pancreatic function in newly diagnosed patients.
- Brand names
- Immunostem
- Other names
- LVV-hPD-L1–modified autologous HSPCs
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on Immunostem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunostem.